Molecular Therapy: Nucleic Acids (Mar 2022)
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
- Maria Teresa Di Martino,
- Mariamena Arbitrio,
- Daniele Caracciolo,
- Alessia Cordua,
- Onofrio Cuomo,
- Katia Grillone,
- Caterina Riillo,
- Giulio Caridà,
- Francesca Scionti,
- Caterina Labanca,
- Caterina Romeo,
- Maria Anna Siciliano,
- Maria D'Apolito,
- Cristina Napoli,
- Martina Montesano,
- Valentina Farenza,
- Valentina Uppolo,
- Michele Tafuni,
- Federica Falcone,
- Giuseppe D'Aquino,
- Natale Daniele Calandruccio,
- Francesco Luciano,
- Licia Pensabene,
- Pierosandro Tagliaferri,
- Pierfrancesco Tassone
Affiliations
- Maria Teresa Di Martino
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy; Corresponding author: Maria Teresa Di Martino, Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
- Mariamena Arbitrio
- Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Catanzaro, Italy
- Daniele Caracciolo
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Alessia Cordua
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Onofrio Cuomo
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Katia Grillone
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Caterina Riillo
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Giulio Caridà
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Francesca Scionti
- Institute for Research and Biomedical Innovation (IRIB), Italian National Council (CNR), Messina, Italy
- Caterina Labanca
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Caterina Romeo
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Maria Anna Siciliano
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Maria D'Apolito
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Cristina Napoli
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Martina Montesano
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Valentina Farenza
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Valentina Uppolo
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Michele Tafuni
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Federica Falcone
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Giuseppe D'Aquino
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Natale Daniele Calandruccio
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Francesco Luciano
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Licia Pensabene
- Department of Surgical and Medical Sciences, Magna Græcia University, Catanzaro, Italy
- Pierosandro Tagliaferri
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy
- Pierfrancesco Tassone
- Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy; Corresponding author: Pierfrancesco Tassone, Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy.
- Journal volume & issue
-
Vol. 27
pp. 1191 – 1224
Abstract
Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests miR-221 as a fine-tuner of chronic liver injury and inflammation-related events. Available information also supports the potential of miR-221 silencing as promising therapeutic intervention. In this systematic review, we selected papers from the principal databases (PubMed, MedLine, Medscape, ASCO, ESMO) between January 2012 and December 2020, using the keywords “miR-221” and the specific keywords related to the most important hematologic and solid malignancies, and some non-malignant diseases, to define and characterize deregulated miR-221 as a valuable therapeutic target in the modern vision of molecular medicine. We found a major role of miR-221 in this view.
